Journal
SCIENTIFIC REPORTS
Volume 11, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41598-021-82833-w
Keywords
-
Categories
Funding
- KOICID
- FONDECYT [11150532, ID17I10037, 3170159]
- FONIS EU-LAC [T010047]
- PAI-CONICYT [79150075]
- FONDEQUIO [EQM180037]
- regional Council of the Los Rios region [FICR16-19, FICR19-20]
- ISCIII Miguel Servet Program [CP19/00200]
- Graduate fellowship ANID [21161365]
- ANID [21160481, 22170632]
- University of Costa Rica
- Becas Santander Iberoamerica Investigacion 2018/2019
- Agencia Espanola de Investigacion AEI/MICIU/FEDER, EU [BIO2017-89081-R]
- CSIC PIE-RDL-COVID-19 (Ministerio de Ciencia e Innovacion from Spain)
Ask authors/readers for more resources
Despite global efforts to develop SARS-CoV-2 treatments, the urgent need for effective diagnosis, treatment, and prophylactic measures remains critical. The development of alpaca Nanobody W25 shows promise as a potential antiviral agent, efficiently neutralizing SARS-CoV-2 strains with high affinity.
Despite unprecedented global efforts to rapidly develop SARS-CoV-2 treatments, in order to reduce the burden placed on health systems, the situation remains critical. Effective diagnosis, treatment, and prophylactic measures are urgently required to meet global demand: recombinant antibodies fulfill these requirements and have marked clinical potential. Here, we describe the fast-tracked development of an alpaca Nanobody specific for the receptor-binding-domain (RBD) of the SARS-CoV-2 Spike protein with potential therapeutic applicability. We present a rapid method for nanobody isolation that includes an optimized immunization regimen coupled with VHH library E. coli surface display, which allows single-step selection of Nanobodies using a simple density gradient centrifugation of the bacterial library. The selected single and monomeric Nanobody, W25, binds to the SARS-CoV-2 S RBD with sub-nanomolar affinity and efficiently competes with ACE-2 receptor binding. Furthermore, W25 potently neutralizes SARS-CoV-2 wild type and the D614G variant with IC50 values in the nanomolar range, demonstrating its potential as antiviral agent.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available